Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / BVS - Bioventus inks contract w/Cigna for Durolane and Gelsyn-3 knee osteoarthritis treatments

BVS - Bioventus inks contract w/Cigna for Durolane and Gelsyn-3 knee osteoarthritis treatments

Bioventus Inc.
Beginning July 1, Cigna (NYSE:CI) commercial members will have access to Bioventus' (NASDAQ:BVS) knee arthritis pain treatments Durolane and Gelsyn-3. Both products contain hyaluronic acid. Durolane is a single injection while Gelsyn-3 is three injections. Read why Seeking Alpha contributor The Value Investor considers Bioventus (BVS) a hold.

For further details see:

Bioventus inks contract w/Cigna for Durolane and Gelsyn-3 knee osteoarthritis treatments
Stock Information
Company Name: Bioventus Inc.
Stock Symbol: BVS
Market: NASDAQ
Website: bioventus.com
Menu
BVS BVS Quote BVS Short BVS News BVS Articles BVS Message Board
Get BVS Alerts

News, Short Squeeze, Breakout and More Instantly...